Sales Recap:

PORTLAND, Maine – February 13, 2014 — ImmuCell Corporation (NASDAQ: ICCC) today announced the results of its operations for the three-month and twelve-month periods ended December 31, 2013.

During the three-month period ended December 31, 2013, product sales increased by 9.7%, or $138,000, to $1,559,000 in comparison to $1,421,000 during the same period in 2012.  During the twelve-month period ended December 31, 2013, product sales increased by 11.5%, or $617,000, to $6,007,000 in comparison to $5,390,000 during the same period in 2012.

“We have now increased product sales during the last six consecutive quarters and for twelve of the last thirteen quarters.  Sales of First Defense® and related product line extensions increased by 16.5% during the fourth quarter and 14.4% during the year ended December 31, 2013,” commented Michael F. Brigham, President and CEO.

The net operating (loss) was ($210,000) during the three-month period ended December 31, 2013, in contrast to a net operating income of $12,000 during the same period in 2012.  The net (loss) was ($151,000), or ($0.05) per share, during the three-month period ended December 31, 2013, in comparison to a net (loss) of ($17,000), or ($0.01) per share, during the same period in 2012.

Net operating (loss) was ($20,000) during the twelve-month period ended December 31, 2013, in contrast to net operating income of $245,000 during the same period in 2012.  Net income was $117,000, or $0.04 per share, during the twelve-month period ended December 31, 2013, in comparison to net income of $90,000, or $0.03 per share, during the same period in 2012.

Regarding the fourth quarter loss, Mr. Brigham added, “During the fourth quarter, we incurred approximately $110,000 in expenses as we initiated our planned investment in a Nisin production plant for Mast Out®.  Further, we reduced production output during the last six months of 2013 in order to replace and repair certain pieces of critical process equipment, which resulted in an increase in cost of goods sold.  We expect our gross margin percentage to be more in line with our historical norms during 2014.”

Cash, cash equivalents and short-term investments increased by 7%, or $342,000, to $5,255,000 as of December 31, 2013, in comparison to $4,914,000 as of December 31, 2012.  Stockholders’ equity increased by 2%, or $201,000, to $9,396,000 as of December 31, 2013, in comparison to $9,195,000 as of December 31, 2012.  The Company had 3,026,000 shares of common stock outstanding as of December 31, 2013.

Annual Report

Quarterly Reports

Proxy Statement
Press Release

SEC Filings – Section 16

View Archive (U.S. Securities and Exchange Commission)   

Form 3 and 3/A
04-01-2014 Paul R Wainman
09-07-2011 David S Cunningham

Form 4 and 4/A
12-08-2011 Joseph H. Crabb
11-16-2011 Michael F Brigham
10-14-2011 David S Cunningham, Bobbi Jo Kunde
08-23-2011 David Scott Tomsche
07-12-2011 David Scott Tomsche
06-23-2011 David Scott Tomsche
08-16-2013 David S Cunningham
08-27-2013 Jonathan E Rothschild
09-17-2013 Jonathan E Rothschild
12-08-2013 Michael F Brigham
12-08-2013 Michael F Brigham

Form 5
No listings at this time